AstraZeneca Plc is to acquire the US specialty pharmaceutical company Alexion Pharmaceuticals Inc for $39 billion – at once giving it five marketed drugs and more than 20 development programmes for rare diseases and immunology. The cash and share offer will be paid in part with an underwritten bridge-financing facility. The transaction is expected to close in the third quarter of 2021 and be immediately earnings accretive.
